Literature DB >> 24135772

α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology.

Isabel Ubeda-Bañon1, Daniel Saiz-Sanchez, Carlos de la Rosa-Prieto, Alino Martinez-Marcos.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disease characterized by bradykinesia, rigidity, resting tremor, and postural instability. Neuropathologically, intracellular aggregates of α-synuclein in Lewy bodies and Lewy neurites appear in particular brain areas according to a sequence of stages. Clinical diagnosis is usually established when motor symptoms are evident (corresponding to Braak stage III or later), years or even decades after onset of the disease. Research at early stages is therefore essential to understand the etiology of PD and improve treatment. Although classically considered as a motor disease, non-motor symptoms have recently gained interest. Olfactory deficits are among the earliest non-motor features of PD. Interestingly, α-synuclein deposits are present in the olfactory bulb and anterior olfactory nucleus at Braak stage I. Several lines of evidence have led to proposals that PD pathology spreads by a prion-like mechanism via the olfactory and vagal systems to the substantia nigra. In this context, current data on the temporal appearance of α-synuclein aggregates in the olfactory system of both humans and transgenic mice are of particular relevance. In addition to the proposed retrograde nigral involvement via brainstem nuclei, olfactory pathways could potentially reach the substantia nigra, and the possibility of centrifugal progression warrants investigation. This review analyzes the involvement of α-synuclein in different elements of the olfactory system, in both humans and transgenic models, from the hodological perspective of possible anterograde and/or retrograde progression of this proteinopathy within the olfactory system and beyond-to the substantia nigra and the remainder of the central and peripheral nervous systems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24135772     DOI: 10.1007/s00429-013-0651-2

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  19 in total

Review 1.  Assessment of direct knowledge of the human olfactory system.

Authors:  Gregory Lane; Guangyu Zhou; Torben Noto; Christina Zelano
Journal:  Exp Neurol       Date:  2020-04-09       Impact factor: 5.330

2.  Early detection of cognitive impairment in Parkinson's disease with the use of the Wisconsin Card Sorting Test: correlations with Montreal Cognitive Assessment and smell identification test.

Authors:  Fumihito Yoshii; Hiroe Onaka; Saori Kohara; Masafuchi Ryo; Wakoh Takahashi; Shigeru Nogawa
Journal:  J Neural Transm (Vienna)       Date:  2019-08-21       Impact factor: 3.575

Review 3.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

Review 4.  Neuropathology correlates of cognitive assessments.

Authors:  Francesca M Brett; Hugh Kearney
Journal:  Ir J Med Sci       Date:  2018-01-18       Impact factor: 1.568

Review 5.  Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.

Authors:  Toshiki Uchihara; Benoit I Giasson
Journal:  Acta Neuropathol       Date:  2015-10-07       Impact factor: 17.088

6.  Differential Effects of Parkinson's Disease on Interneuron Subtypes within the Human Anterior Olfactory Nucleus.

Authors:  Isabel Ubeda-Bañon; Alicia Flores-Cuadrado; Daniel Saiz-Sanchez; Alino Martinez-Marcos
Journal:  Front Neuroanat       Date:  2017-12-05       Impact factor: 3.856

7.  The Olfactory System Revealed: Non-Invasive Mapping by using Constrained Spherical Deconvolution Tractography in Healthy Humans.

Authors:  Demetrio Milardi; Alberto Cacciola; Alessandro Calamuneri; Maria F Ghilardi; Fabrizia Caminiti; Filippo Cascio; Veronica Andronaco; Giuseppe Anastasi; Enricomaria Mormina; Alessandro Arrigo; Daniele Bruschetta; Angelo Quartarone
Journal:  Front Neuroanat       Date:  2017-04-10       Impact factor: 3.856

8.  Statin adherence and the risk of Parkinson's disease: A population-based cohort study.

Authors:  Violetta Rozani; Nir Giladi; Baruch El-Ad; Tanya Gurevich; Judith Tsamir; Beatriz Hemo; Chava Peretz
Journal:  PLoS One       Date:  2017-04-07       Impact factor: 3.240

9.  Neurodegeneration and contralateral α-synuclein induction after intracerebral α-synuclein injections in the anterior olfactory nucleus of a Parkinson's disease A53T mouse model.

Authors:  Alicia Flores-Cuadrado; Daniel Saiz-Sanchez; Alicia Mohedano-Moriano; Alino Martinez-Marcos; Isabel Ubeda-Bañon
Journal:  Acta Neuropathol Commun       Date:  2019-04-15       Impact factor: 7.801

10.  The predictive value of SS-16 in clinically diagnosed Parkinson's disease patients: comparison with (99m)Tc-TRODAT-1 SPECT scans.

Authors:  Wenyan Kang; Fangyi Dong; Dunhui Li; Thomas J Quinn; Shengdi Chen; Jun Liu
Journal:  Transl Neurodegener       Date:  2016-08-20       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.